NCT00307021已完成2 期
Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Occurrence of SAEs.
研究概览
简要总结
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas. The candidate vaccines are designed to offer protection against malaria disease due to the parasite Plasmodium falciparum. Candidate vaccines containing the RTS,S antigen would also provide protection against infection with hepatitis B virus (HBV). This study will evaluate two candidate vaccines. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Months 至 48 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or female child between 18 months and 4 years of age (up to but not including 5th birthday) at the time of first vaccination.
- •Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.
- •Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits)
排除标准
- •Acute disease at the time of enrolment.
- •Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.
- •Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of range.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid.
- •Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Previous participation in any other malaria vaccine trial.
- •Simultaneous participation in any other clinical trial.
- •Same sex twin.
- •History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
研究组 & 干预措施
Group A
Active Comparator
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (Biological)
Group B
Experimental
干预措施: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (Biological)
结局指标
主要结局
Occurrence of SAEs.
时间窗: From the time of first vaccination until one month post Dose 3
Antibody titers to the P. falciparum circumsporozoite repeat domain (anti-CS).
时间窗: One month post Dose 3.
次要结局
- Anti-Hepatitis B surface agent (anti-HBs) antibody titers.(Prior to vaccination, one month post Dose 2 and one month post Dose 3.)
- Occurrence of unsolicited symptoms.(After each vaccination over a 30-day follow-up)
- Anti-CS antibody titers.(Prior to vaccination, one month post Dose 2)
- Occurrence of solicited general and local reactions.(Over a 7-day follow-up period after each vaccination.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.MalariaNCT00197067GlaxoSmithKline200
已完成
2 期
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI RegimenMalariaNCT00436007GlaxoSmithKline511
已完成
2 期
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian InfantsMalaria VaccinesMalariaNCT00289185GlaxoSmithKline340
已完成
3 期
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and ChildrenMalariaNCT01148459GlaxoSmithKline200
已完成
2 期
Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African InfantsMalariaNCT01231503GlaxoSmithKline480